Literature DB >> 18546616

Classification of ovarian cancer: a genomic analysis.

Michael P Stany, Tomas Bonome, Fred Wamunyokoli, Kristen Zorn, Laurent Ozbun, Dong-Choon Park, Ke Hao, Jeff Boyd, Anil K Sood, David M Gershenson, Ross S Berkowitz, Samuel C Mok, Michael J Birrer.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18546616      PMCID： PMC6953390          DOI： 10.1007/978-0-387-68969-2_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  30 in total

Review 1.  RHO-GTPases and cancer.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

2.  Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning.

Authors:  A M Chan; S Takai; K Yamada; T Miki
Journal:  Oncogene       Date:  1996-03-21       Impact factor: 9.867

3.  Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.

Authors:  P X Li; J Wong; A Ayed; D Ngo; A M Brade; C Arrowsmith; R C Austin; H J Klamut
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

4.  Genetic analysis of early- versus late-stage ovarian tumors.

Authors:  V Shridhar; J Lee; A Pandita; S Iturria; R Avula; J Staub; M Morrissey; E Calhoun; A Sen; K Kalli; G Keeney; P Roche; W Cliby; K Lu; R Schmandt; G B Mills; R C Bast; C D James; F J Couch; L C Hartmann; J Lillie; D I Smith
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

5.  Presence of genetic alterations in microdissected stroma of human colon and breast cancers.

Authors:  N Wernert; C Löcherbach; A Wellmann; P Behrens; A Hügel
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

6.  Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.

Authors:  Gunamani Sithanandam; Laura W Fornwald; Janet Fields; Lucy M Anderson
Journal:  Oncogene       Date:  2005-03-10       Impact factor: 9.867

7.  Cloning and characterization of the human activity-dependent neuroprotective protein.

Authors:  R Zamostiano; A Pinhasov; E Gelber; R A Steingart; E Seroussi; E Giladi; M Bassan; Y Wollman; H J Eyre; J C Mulley; D E Brenneman; I Gozes
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

8.  Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Authors:  T Sugiyama; T Kamura; J Kigawa; N Terakawa; Y Kikuchi; T Kita; M Suzuki; I Sato; K Taguchi
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

Review 9.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

10.  Cell cycle regulation and p53 activation by protein phosphatase 2C alpha.

Authors:  Paula Ofek; Daniella Ben-Meir; Zehavit Kariv-Inbal; Moshe Oren; Sara Lavi
Journal:  J Biol Chem       Date:  2003-01-03       Impact factor: 5.157
View more
  5 in total

1.  Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Authors:  Hua Li; Qi Cai; Andrew K Godwin; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2010-11-29       Impact factor: 5.852

2.  A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.

Authors:  Robert S Mannel; Mark F Brady; Elise C Kohn; Parviz Hanjani; Masamichi Hiura; Roger Lee; Koen Degeest; David E Cohn; Bradley J Monk; Helen Michael
Journal:  Gynecol Oncol       Date:  2011-05-06       Impact factor: 5.482

3.  Clinicopathologic and gene expression parameters predict liver cancer prognosis.

Authors:  Ke Hao; John Lamb; Chunsheng Zhang; Tao Xie; Kai Wang; Bin Zhang; Eugene Chudin; Nikki P Lee; Mao Mao; Hua Zhong; Danielle Greenawalt; Mark D Ferguson; Irene O Ng; Pak C Sham; Ronnie T Poon; Cliona Molony; Eric E Schadt; Hongyue Dai; John M Luk
Journal:  BMC Cancer       Date:  2011-11-09       Impact factor: 4.430

4.  Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens.

Authors:  Chien An Chen; Chun Ju Chiang; Yun Yuan Chen; San Lin You; Shu Feng Hsieh; Chao Hsiun Tang; Wen Fang Cheng
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

5.  Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.

Authors:  Ke Hao; John M Luk; Nikki P Y Lee; Mao Mao; Chunsheng Zhang; Mark D Ferguson; John Lamb; Hongyue Dai; Irene O Ng; Pak C Sham; Ronnie T P Poon
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.